Kiniksa Pharmaceuticals International, plc
KNSA
Hisse Senetlerindeki Sıralama
#2918
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Hisse Fiyatı
$80.10
Son senkronizasyon: 2026-10-21
Piyasa Değeri
$6.25B
Değişim (1 gün)
-3.69%
Değişim (1 yıl)
105.92%
Ülke
GB
Ticaret Kiniksa Pharmaceuticals International, plc (KNSA)
Kategori
Healthcare
Kiniksa Pharmaceuticals International, plc (KNSA) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $78.59 - 2026-10-01
Gün sonu en düşük fiyat: $18.08 - 2018-05-01
Gün sonu en düşük fiyat: $18.08 - 2018-05-01
Kiniksa Pharmaceuticals International, plc için hisse fiyatı geçmişi: 2018 - 2026
Yıllık Hisse Fiyatı Performansı
| Yıl | Performans |
|---|---|
| 2026 (TTM) | 31.83% |
| 2025 | 101.55% |
| 2024 | 16.14% |
| 2023 | 13.98% |
| 2022 | 22.63% |
| 2021 | -31.53% |
| 2020 | 57.49% |
| 2019 | -47.95% |
| 2018 | 0.00% |
Benzer şirketler veya rakiplerin hisse fiyatı
| Şirket | Hisse fiyatı | Değişim 1yıl% | Ülke |
|---|---|---|---|
| $62.20 | 68.82% |
US
|
|
| $46.29 | 37.83% |
SE
|
|
| $171.04 | 23.67% |
FR
|
|
| $116.39 | 58.03% |
US
|
|
| $59.46 | -0.57% |
IT
|
